Affiliation:
1. Semey Medical University
2. Corporate Fund “University Medical Center”
3. Astana Medical University
4. Almazov National Medical Research Centre
Abstract
Objective. Development of principles for personalized selection of patients for renal denervation (RD) based on the evaluation of procedural response predictors. Design and methods. In the period from 2016 to 2022, 91 patients with resistant arterial hypertension (RHTN) underwent a RD procedure using 2 types of catheters — monopolar and spiral. All patients were assessed for basic demographic, clinical, functional, and laboratory characteristics. The reassessment was carried out on the 7th day, then after 6 and 12 months. A predictive model for determining the probability of response to RD was constructed using the logistic regression method. Results. The final analysis included data from 91 RHTN patients, the mean age was 57,79 ± 9,5 years. At baseline, patients received 4,5 ± 1,4 antihypertensive drugs. Initial office systolic blood pressure (SBP) was 190 (interquartile range (IQR) 100; 140, 240) mm Hg, diastolic blood pressure (DBP) — 100 (IQR 60; 80, 140) mm Hg. Among the responders, a significant reduction in blood pressure (BP) was achieved, with maintenance of the antihypertensive effect during 1 year of follow-up (p < 0,001 for SBP and DBP). The multivariate regression analysis showed that the initial DPB (p < 0,001), the diameter of the right (p = 0,049) and left renal arteries (RA) (p = 0,038) were significant predictors. Based on these data, a prognostic model was developed (p < 0,001). Conclusions. Our results confirmed effectiveness and safety of RD. The stability of the clinical effect is important. However, there was a high variability in the degree of BP reduction after the procedure. The initial DBP, the diameter of the left and right RA, and the use of drugs that reduce the activity of the sympathetic nervous system can be used as possible predictors of response to RD.
Publisher
Arterialnaya Gipertenziya
Subject
Cardiology and Cardiovascular Medicine,Internal Medicine
Reference31 articles.
1. Abbafati C, GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019:a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249. doi:10.1016/S01406736(20)30752-2
2. Balanova YuA, Shalnova SA, Imaeva AE, Kapustina АУ, Muromtseva GA, Evstifeeva SV et al. Prevalence, awareness, treatment and control of hypertension in Russian Federation (data of observational ESSE-RF-2 Study). Rat Pharmacother Cardiol. 2019;15(4):450-466. doi:10.20996/1819-6446-2019-15-4-450-466. In Russian.
3. Supiyev A, Kossumov A, Utepova L, Nurgozhin T, Zhumadilov Z, Bobak M. Prevalence, awareness, treatment and control of arterial hypertension in Astana, Kazakhstan. A crosssectional study. Public Health. 2015;129(7):948-953. doi:10.1016/j.puhe.2015.02.020
4. SPRINT Research Group, Jackson TW, Jeff DW, Paul KW, Snyder JK, Sink KM, Rocco MV et al. A randomized trial of intensive versus standard blood-pressure control. The SPRINT Research Group. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939
5. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sunet G al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385(14):1268-1279. doi:10.1056/NEJMoa2111437